Browse by Journal Title

2023

Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al.
Immisch, L. and Papafotiou, G. and Popp, O. and Mertins, P. and Blankenstein, T. and Willimsky, G.
Journal for ImmunoTherapy of Cancer 11 (3): e006784. 14 March 2023

Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy.
Plewa, N. and Poncette, L. and Blankenstein, T.
Journal for ImmunoTherapy of Cancer 11 (2): e006001. February 2023

2022

TIGIT blockade repolarizes AML-associated TIGIT(+) M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis.
Brauneck, F. and Fischer, B. and Witt, M. and Muschhammer, J. and Oelrich, J. and da Costa Avelar, P.H. and Tsoka, S. and Bullinger, L. and Seubert, E. and Smit, D.J. and Bokemeyer, C. and Ackermann, C. and Wellbrock, J. and Haag, F. and Fiedler, W.
Journal for ImmunoTherapy of Cancer 10 (12): e004794. 22 December 2022

H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2(+) patients with diffuse midline glioma.
Immisch, L. and Papafotiou, G. and Popp, O. and Mertins, P. and Blankenstein, T. and Willimsky, G.
Journal for ImmunoTherapy of Cancer 10 (10): e005535. 27 October 2022

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL.
Rejeski, K. and Perez, A. and Iacoboni, G. and Penack, O. and Bücklein, V. and Jentzsch, L. and Mougiakakos, D. and Johnson, G. and Arciola, B. and Carpio, C. and Blumenberg, V. and Hoster, E. and Bullinger, L. and Locke, F.L. and von Bergwelt-Baildon, M. and Mackensen, A. and Bethge, W. and Barba, P. and Jain, M.D. and Subklewe, M.
Journal for ImmunoTherapy of Cancer 10 (5): e004475. 17 May 2022

2021

Acute kidney injury in patients treated with immune checkpoint inhibitors.
Gupta, S. and Short, S.A.P. and Sise, M.E. and Prosek, J.M. and Madhavan, S.M. and Soler, M.J. and Ostermann, M. and Herrmann, S.M. and Abudayyeh, A. and Anand, S. and Glezerman, I. and Motwani, S.S. and Murakami, N. and Wanchoo, R. and Ortiz-Melo, D.I. and Rashidi, A. and Sprangers, B. and Aggarwal, V. and Malik, A.B. and Loew, S. and Carlos, C.A. and Chang, W.T. and Beckerman, P. and Mithani, Z. and Shah, C.V. and Renaghan, A.D. and Seigneux, S.D. and Campedel, L. and Kitchlu, A. and Shin, D.S. and Rangarajan, S. and Deshpande, P. and Coppock, G. and Eijgelsheim, M. and Seethapathy, H. and Lee, M.D. and Strohbehn, I.A. and Owen, D.H. and Husain, M. and Garcia-Carro, C. and Bermejo, S. and Lumlertgul, N. and Seylanova, N. and Flanders, L. and Isik, B. and Mamlouk, O. and Lin, J.S. and Garcia, P. and Kaghazchi, A. and Khanin, Y. and Kansal, S.K. and Wauters, E. and Chandra, S. and Schmidt-Ott, K.M. and Hsu, R.K. and Tio, M.C. and Sarvode Mothi, S. and Singh, H. and Schrag, D. and Jhaveri, K.D. and Reynolds, K.L. and Cortazar, F.B. and Leaf, D.E.
Journal for ImmunoTherapy of Cancer 9 (10): e003467. October 2021

High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies.
Çınar, Ö. and Brzezicha, B. and Grunert, C. and Kloetzel, P.M. and Beier, C. and Peuker, C.A. and Keller, U. and Pezzutto, A. and Busse, A.
Journal for ImmunoTherapy of Cancer 9 (7): e002410. 30 July 2021